Stock Events

Stock Events

Eocene 

$3.84
28
-$0.76-16.52% Friday 19:59

Statistics

Day High
4.63
Day Low
3.82
52W High
4.88
52W Low
3.27
Volume
301,155
Avg. Volume
49,355
Mkt Cap
4.1M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25NovExpected
Q3 2024
Q1 2025
Q1 2025
Q2 2025
Q3 2025
Q2 2026
Next
-3.12
-2.19
-1.26
-0.33
Expected EPS
-3.06
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-10.31MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLMD. It's not an investment recommendation.
Alphabet
4
GOOGL
AMD
4
AMD
Apple
3
AAPL
Amazon
3
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.28B
Madrigal Pharmaceuticals is developing treatments for NASH, directly competing with Galmed's pipeline.
Viking Therapeutics
VKTX
Mkt Cap3.38B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap186.13B
Gilead Sciences has a strong pipeline in liver disease treatments, including NASH, positioning it as a competitor.
Agios Pharmaceuticals
AGIO
Mkt Cap1.97B
Agios Pharmaceuticals, though primarily focused on cancer, has expanded into metabolic disorders, potentially competing in the NASH space.
Novartis
NVS
Mkt Cap266.8B
Novartis AG, a large pharmaceutical company, has interests in developing treatments for liver diseases, including NASH, making it a competitor.
Abbvie
ABBV
Mkt Cap466.45B
AbbVie Inc. has a diverse portfolio that includes research in liver diseases, potentially putting it in competition with Galmed.
Pfizer
PFE
Mkt Cap157.65B
Pfizer Inc. is involved in developing treatments for a wide range of conditions, including liver diseases, which could compete with Galmed's products.
Merck
MRK
Mkt Cap362.35B
Merck & Co., Inc. has a broad research portfolio that could include NASH treatments, positioning it as a potential competitor.

About

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.
Show more...
CEO
Allen J. Baharaff
Employees
6
Country
Israel
ISIN
IL0011313900
WKN
000A1XFUX

Listings

STU
DE
GPH.STU
F
DE
GPH.F
XNAS
US
EOCN
OTCM
US
GLMD

0 Comments

Share your thoughts

FAQ

What is Eocene stock price today?▼
The current price of GLMD is $3.84 USD — it has decreased by -16.52% in the past 24 hours. Watch Eocene stock price performance more closely on the chart.
What is Eocene stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Eocene stocks are traded under the ticker GLMD.
Is Eocene stock price growing?▼
GLMD stock has risen by +0% compared to the previous week, the month change is a -10.8% fall, over the last year Eocene has showed a -65.22% decrease.
What is Eocene market cap?▼
Today Eocene has the market capitalization of 4.1M
When is the next Eocene earnings date?▼
Eocene is going to release the next earnings report on November 25, 2026.
What were Eocene earnings last quarter?▼
GLMD earnings for the last quarter are -2.86 USD per share, whereas the estimation was -3.12 USD resulting in a +8.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Eocene revenue for the last year?▼
Eocene revenue for the last year amounts to 0 USD.
What is Eocene net income for the last year?▼
GLMD net income for the last year is -10.31M USD.
How many employees does Eocene have?▼
As of September 25, 2026, the company has 6 employees.
In which sector is Eocene located?▼
Eocene operates in the Health & Wellness sector.
When did Eocene complete a stock split?▼
The last stock split for Eocene was on August 19, 2026 with a ratio of 1:8.
Where is Eocene headquartered?▼
Eocene is headquartered in Ramat Gan, Israel.